Financial Review: Nyxoah (NASDAQ:NYXH) versus Electromed (NYSE:ELMD)

Electromed (NYSE:ELMD) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Electromed and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0	1	3	0	2.75
Nyxoah	1	1	2	0	2.25

Electromed currently has a consensus target price of $43.75, indicating a potential upside of 64.35%. Nyxoah has a consensus target price of $4.26, indicating a potential upside of 397.66%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Electromed.

Insider & Institutional Ownership

40.8% of Electromed shares are held by institutional investors. 11.0% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Electromed has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares Electromed and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Nyxoah	-443.16%	-178.90%	-81.83%

Earnings & Valuation

This table compares Electromed and Nyxoah”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78 million	2.99	$5.15 million	$1.31	20.32
Nyxoah	$11.33 million	2.93	-$101.92 million	($2.52)	-0.34

Electromed has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Summary

Electromed beats Nyxoah on 12 of the 14 factors compared between the two stocks.

About Electromed

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.